Belen Arranz, MD, is affiliated with MERITT at Institut de Recerca Sant Joan de Déu, Parc Sanitari Sant Joan de Déu, and CIBERSAM in Spain. Her research, published between 2004 and 2024, focuses on schizophrenia and schizoaffective disorders, anxiety, and major depressive disorder. She has examined inflammatory biomarkers in first-episode psychosis and investigated insulin resistance and glucose metabolism in patients with schizophrenia treated with antipsychotics.
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.
